{"id":"empa","safety":{"commonSideEffects":[{"rate":"8–13","effect":"Genital mycotic infections"},{"rate":"4–8","effect":"Urinary tract infections"},{"rate":"3–5","effect":"Polyuria"},{"rate":"2–4","effect":"Hypotension"},{"rate":"0.1–0.2","effect":"Diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":{"setId":"5777b8a8-ada6-4950-8548-43a1de11f075","title":"JARDIANCE (EMPAGLIFLOZIN) TABLET, FILM COATED [CARDINAL HEALTH 107, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Empagliflozin selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the nephron. By blocking SGLT2, the drug prevents reabsorption of filtered glucose, leading to increased urinary glucose excretion (glycosuria) and reduced blood glucose concentrations. This mechanism is independent of insulin secretion or action, making it effective across a range of glycemic states.","oneSentence":"Empagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, promoting urinary glucose excretion and lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:19.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Swiss_Federal_Laboratories_for_Materials_Science_and_Technology","title":"Swiss Federal Laboratories for Materials Science and Technology","extract":"The Swiss Federal Laboratories for Materials Science and Technology is a Swiss research institution for application-oriented materials science and technology. It has three locations – Dübendorf, St. Gallen and Thun. As part of the ETH Domain, it is assigned to the Federal Department of Economic Affairs, Education and Research (EAER). For more than 100 years since its foundation in 1880, Empa has been a material testing institute. Since the late 1980s, it has increasingly transformed into an interdisciplinary research institute for materials and technologies."},"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT07107945","phase":"PHASE3","title":"A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-12-09","conditions":"Chronic Kidney Disease","enrollment":120},{"nctId":"NCT07472920","phase":"NA","title":"Empagliflozin Adjunctive Therapy in Bipolar Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2026-03-09","conditions":"Bipolar Disorder, Bipolar Depression, Insulin Resistance","enrollment":20},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07363707","phase":"PHASE4","title":"A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2023-05-01","conditions":"NAFLD (Nonalcoholic Fatty Liver Disease)","enrollment":108},{"nctId":"NCT07074418","phase":"PHASE4","title":"Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2026-04","conditions":"Chronic Kidney Diseases","enrollment":34},{"nctId":"NCT07336797","phase":"PHASE2","title":"Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy","status":"RECRUITING","sponsor":"Abdelrahman Mahmoud","startDate":"2025-09-01","conditions":"Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)","enrollment":66},{"nctId":"NCT06391450","phase":"PHASE4","title":"Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hannover Medical School","startDate":"2024-06-14","conditions":"Autosomal Dominant Polycystic Kidney","enrollment":44},{"nctId":"NCT05081219","phase":"PHASE2","title":"SNIFF - Combo INI+EMPA Trial","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-09-14","conditions":"Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease","enrollment":47},{"nctId":"NCT07175051","phase":"PHASE2","title":"Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-12","conditions":"Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria","enrollment":20},{"nctId":"NCT07146880","phase":"PHASE2","title":"Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-15","conditions":"Brugada Syndrome (BrS)","enrollment":10},{"nctId":"NCT05138575","phase":"PHASE2","title":"SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-01-24","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":53},{"nctId":"NCT03594110","phase":"PHASE3","title":"EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-01-31","conditions":"Chronic Kidney Disease","enrollment":6609},{"nctId":"NCT06729996","phase":"PHASE2","title":"Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-05-29","conditions":"Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes Mellitus","enrollment":40},{"nctId":"NCT06955260","phase":"PHASE3","title":"SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure","status":"NOT_YET_RECRUITING","sponsor":"Subodh Verma","startDate":"2025-05","conditions":"Congenital Heart Disease","enrollment":410},{"nctId":"NCT03464045","phase":"","title":"Empa PASS on Urinary Tract Malignancies","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-11-16","conditions":"Diabetes Mellitus, Type 2","enrollment":344995},{"nctId":"NCT06846411","phase":"PHASE4","title":"The EMPA-FIT Study","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2024-01-01","conditions":"Diabetes, Diabetes Mellitus, Type II","enrollment":46},{"nctId":"NCT05911724","phase":"","title":"Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2023-03-01","conditions":"Stable Angina, Heart Failure","enrollment":180},{"nctId":"NCT06095492","phase":"NA","title":"Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus","status":"RECRUITING","sponsor":"Medanta, The Medicity, India","startDate":"2023-10-30","conditions":"Kidney Transplant; Complications, Diabetes Mellitus","enrollment":200},{"nctId":"NCT06715449","phase":"PHASE2, PHASE3","title":"EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source","status":"RECRUITING","sponsor":"University of East Anglia","startDate":"2024-11-22","conditions":"Embolic Stroke of Undetermined Source, Atrial Fibrillation New Onset","enrollment":100},{"nctId":"NCT06313008","phase":"NA","title":"Empagliflozin Versus Vildagliptin in CAD Patients With T2DM","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2023-08-10","conditions":"Coronary Artery Disease, Type 2 Diabetes","enrollment":120},{"nctId":"NCT06641128","phase":"PHASE4","title":"The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2024-10-15","conditions":"Rheumatoid Arthritis (RA), Methotrexate Induced Nephrotoxicity, Methotrexate Adverse Reaction","enrollment":44},{"nctId":"NCT04295005","phase":"","title":"A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-11-16","conditions":"Diabetes Mellitus, Type 2","enrollment":24500},{"nctId":"NCT03200860","phase":"PHASE2","title":"Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2017-12-18","conditions":"Heart Failure Acute, Heart Failure，Congestive, Heart Failure; With Decompensation","enrollment":80},{"nctId":"NCT04937816","phase":"","title":"This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-06-01","conditions":"Diabetes Mellitus, Type 2","enrollment":16746},{"nctId":"NCT06117137","phase":"PHASE3","title":"The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-11-15","conditions":"Fatty Liver, Nonalcoholic","enrollment":150},{"nctId":"NCT06103279","phase":"PHASE2, PHASE3","title":"Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-11","conditions":"Cancer","enrollment":40},{"nctId":"NCT04215536","phase":"","title":"Replication of the EMPAREG Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-07-08","conditions":"Diabetes","enrollment":103752},{"nctId":"NCT04910178","phase":"PHASE4","title":"Follow-up of NAFLD Patients With MRI-PDFF","status":"COMPLETED","sponsor":"Asmaa Abdelfattah Elsayed","startDate":"2020-12-01","conditions":"Diabetes Type 2, NAFLD","enrollment":80},{"nctId":"NCT03554200","phase":"PHASE2","title":"EMPA Acute Heart Failure","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2018-06-11","conditions":"Diabetes Mellitus, Type 2, Acute Heart Failure","enrollment":19},{"nctId":"NCT04201496","phase":"PHASE1","title":"SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Ananda Basu, MD","startDate":"2020-02-24","conditions":"Type 1 Diabetes","enrollment":34},{"nctId":"NCT05373004","phase":"PHASE2, PHASE3","title":"Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"Omar Tarek Elfarargi","startDate":"2023-03","conditions":"Diabetic Nephropathy Type 2","enrollment":212},{"nctId":"NCT05283057","phase":"PHASE3","title":"Empagliflozin in Patients With Glomerulonephritis","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2020-02-20","conditions":"Glomerulonephritis, Proteinuria","enrollment":50},{"nctId":"NCT03433248","phase":"PHASE4","title":"Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES","status":"UNKNOWN","sponsor":"M.H.H. Kramer","startDate":"2017-11-09","conditions":"Type2 Diabetes","enrollment":66},{"nctId":"NCT03332212","phase":"PHASE3","title":"A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-03-01","conditions":"Heart Failure","enrollment":72},{"nctId":"NCT04098575","phase":"","title":"A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-09-16","conditions":"Diabetes Mellitus, Type 2","enrollment":9571},{"nctId":"NCT03485222","phase":"PHASE4","title":"Are the \"Cardiac Benefits\" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-05-21","conditions":"Cardiovascular Diseases","enrollment":84},{"nctId":"NCT03128528","phase":"PHASE2","title":"Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2017-07-01","conditions":"Chronic Heart Failure","enrollment":84},{"nctId":"NCT02833415","phase":"PHASE4","title":"Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-03","conditions":"Obesity, Visceral","enrollment":40},{"nctId":"NCT02453555","phase":"PHASE3","title":"Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-05-14","conditions":"Diabetes Mellitus, Type 2","enrollment":275},{"nctId":"NCT03473262","phase":"","title":"Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2017-01-01","conditions":"Diabetes Mellitus, Type 2","enrollment":200},{"nctId":"NCT02815644","phase":"PHASE1","title":"Empa/Lina FDC Food Effect Study (Japan)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-07-15","conditions":"Healthy","enrollment":22},{"nctId":"NCT02702011","phase":"PHASE2","title":"Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-03-20","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT02854748","phase":"PHASE1","title":"Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2016-08","conditions":"Diabetes Mellitus, Type II","enrollment":30},{"nctId":"NCT01131676","phase":"PHASE3","title":"BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-07","conditions":"Diabetes Mellitus, Type 2","enrollment":7064},{"nctId":"NCT01719003","phase":"PHASE3","title":"Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-10","conditions":"Diabetes Mellitus, Type 2, Hyperglycemia","enrollment":1413}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CATHETERISATION CARDIAC"},{"count":1,"reaction":"CORONARY ANGIOPLASTY"},{"count":1,"reaction":"CORONARY ARTERIAL STENT INSERTION"},{"count":1,"reaction":"FEBRILE NEUTROPENIA"},{"count":1,"reaction":"INJECTION SITE WARMTH"},{"count":1,"reaction":"PAIN IN EXTREMITY"},{"count":1,"reaction":"SEPSIS"},{"count":1,"reaction":"VASCULAR PAIN"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Empa","genericName":"Empa","companyName":"Beni-Suef University","companyId":"beni-suef-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Empagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, promoting urinary glucose excretion and lowering blood glucose levels. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}